Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
IMMUNIC, INC. (VTL) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 8-K Investor presentation
Docs: "Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis",
"Presentation"
08/21/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/03/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/03/2023 8-K Quarterly results
Docs: "Immunic, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update",
"Presentation"
06/30/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
06/29/2023 4 HOWSON TAMAR D (Director) has filed a Form 4 on IMMUNIC, INC.
Txns: Granted 16,000 options @ $1.94, valued at $31k
06/29/2023 4 PHILLIPS BARCLAY A (Director) has filed a Form 4 on IMMUNIC, INC.
Txns: Granted 16,000 options @ $1.94, valued at $31k
06/29/2023 4 Rudick Richard Alan (Director) has filed a Form 4 on IMMUNIC, INC.
Txns: Granted 16,000 options @ $1.94, valued at $31k
06/29/2023 4 Neermann Joerg (Director) has filed a Form 4 on IMMUNIC, INC.
Txns: Granted 16,000 options @ $1.94, valued at $31k
06/29/2023 4 Toernsen Monika Maria (Director) has filed a Form 4 on IMMUNIC, INC.
Txns: Granted 16,000 options @ $1.94, valued at $31k
05/16/2023 4 Whaley Glenn (CFO) has filed a Form 4 on IMMUNIC, INC.
Txns: Bought 5,000 shares @ $1.75, valued at $8.8k
05/11/2023 8-K Quarterly results
Docs: "Immunic, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update"
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/04/2023 8-K Quarterly results
05/01/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/27/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/27/2023 3 Form 3 - Initial statement of beneficial ownership of securities:
04/27/2023 8-K Quarterly results
04/05/2023 8-K Investor presentation
Docs: "Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis",
"Presentation"
03/13/2023 8-K Regulation FD Disclosure  Interactive Data
02/24/2023 SC 13D/A LSP V Cooperatieve U.A. reports a 4.9% stake in IMMUNIC, INC.
02/23/2023 10-K Annual Report for the period ended December 31, 2022
02/23/2023 8-K Quarterly results
Docs: "Immunic, Inc. Reports Year End 2022 Financial Results and Provides Corporate Update",
"Presentation"
02/14/2023 SC 13G/A COMMODORE CAPITAL LP reports a 6.3% stake in Immunic, Inc.
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/13/2023 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
02/09/2023 8-K Quarterly results
01/06/2023 4 Muehler Andreas (Chief Medical Officer) has filed a Form 4 on IMMUNIC, INC.
Txns: Granted 132,000 options @ $1.4, valued at $184.8k
01/06/2023 4 Nash Duane (Executive Chairman) has filed a Form 4 on IMMUNIC, INC.
Txns: Granted 132,000 options @ $1.4, valued at $184.8k
01/06/2023 4 Whaley Glenn (CFO) has filed a Form 4 on IMMUNIC, INC.
Txns: Granted 110,000 options @ $1.4, valued at $154k
01/06/2023 4 Vitt Daniel (CEO) has filed a Form 4 on IMMUNIC, INC.
Txns: Granted 300,000 options @ $1.4, valued at $420k
12/30/2022 8-K Quarterly results
12/21/2022 EFFECT Form EFFECT - Notice of Effectiveness:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy